Literature DB >> 9180082

Essential role of growth hormone in ischemia-induced retinal neovascularization.

L E Smith1, J J Kopchick, W Chen, J Knapp, F Kinose, D Daley, E Foley, R G Smith, J M Schaeffer.   

Abstract

Retinal neovascularization is the major cause of untreatable blindness. The role of growth hormone (GH) in ischemia-associated retinal neovascularization was studied in transgenic mice expressing a GH antagonist gene and in normal mice given an inhibitor of GH secretion (MK678). Retinal neovascularization was inhibited in these mice in inverse proportion to serum levels of GH and a downstream effector, insulin-like growth factor-I (IGF-I). Inhibition was reversed with exogenous IGF-I administration. GH inhibition did not diminish hypoxia-stimulated retinal vascular endothelial growth factor (VEGF) or VEGF receptor expression. These data suggest that systemic inhibition of GH or IGF-I, or both, may have therapeutic potential in preventing some forms of retinopathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180082     DOI: 10.1126/science.276.5319.1706

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  77 in total

1.  Innervation of the uvea by galanin and somatostatin immunoreactive axons in macaques and baboons.

Authors:  Sally I Firth; Paul L Kaufman; Baptiste J De Jean; John M Byers; David W Marshak
Journal:  Exp Eye Res       Date:  2002-07       Impact factor: 3.467

Review 2.  GH receptor antagonist: mechanism of action and clinical utility.

Authors:  Sowmya K Surya; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 3.  Retinopathy of prematurity.

Authors:  Ann Hellström; Lois E H Smith; Olaf Dammann
Journal:  Lancet       Date:  2013-06-17       Impact factor: 79.321

Review 4.  Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

Authors:  Nicholas A Tritos; Beverly M K Biller
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina.

Authors:  Andrei A Kramerov; Mehrnoosh Saghizadeh; Hao Pan; Andrea Kabosova; Mathias Montenarh; Khalil Ahmed; John S Penn; Candy K Chan; David R Hinton; Maria B Grant; Alexander V Ljubimov
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

6.  Plasma endothelin-1 concentrations in patients with retinal vein occlusions.

Authors:  A Iannaccone; C Letizia; S Pazzaglia; E M Vingolo; G Clemente; M R Pannarale
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

7.  Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT.

Authors:  E Zelzer; Y Levy; C Kahana; B Z Shilo; M Rubinstein; B Cohen
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.

Authors:  L Yang; S C Berk; S P Rohrer; R T Mosley; L Guo; D J Underwood; B H Arison; E T Birzin; E C Hayes; S W Mitra; R M Parmar; K Cheng; T J Wu; B S Butler; F Foor; A Pasternak; Y Pan; M Silva; R M Freidinger; R G Smith; K Chapman; J M Schaeffer; A A Patchett
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease.

Authors:  Jesús Ruberte; Eduard Ayuso; Marc Navarro; Ana Carretero; Víctor Nacher; Virginia Haurigot; Mónica George; Cristina Llombart; Alba Casellas; Cristina Costa; Assumpció Bosch; Fatima Bosch
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

10.  FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1.

Authors:  Chandra S Boosani; Narasimharao Nalabothula; Veerendra Munugalavadla; Dominic Cosgrove; Venkateshwar G Keshamoun; Nader Sheibani; Akulapalli Sudhakar
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-14       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.